Why are Healius shares crashing 35% on Wednesday?

This healthcare share is crashing deep into the red on Wednesday. What's happening?

| More on:
A woman looks shocked as she drinks a coffee while reading the paper.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Healius Ltd (ASX: HLS) shares are back from their trading halt and crashing deep into the red.

In morning trade, the healthcare company's shares are down 35% to $1.19.

As a comparison, the ASX 200 index is trading broadly flat.

Why are Healius shares crashing?

Investors have been hitting the sell button today after the company completed the institutional component of a heavily discounted entitlement offer.

According to the release, the company has raised a total of approximately $154 million at $1.20 per new share. This represents a 35% discount to where Healius shares last traded.

The company notes that the institutional entitlement offer was well supported by existing Healius institutional shareholders. Approximately 92% of entitlements available to eligible institutional shareholders were taken up.

Entitlements not taken up by eligible institutional shareholders and entitlements of ineligible institutional shareholders were sold at the $1.20 per share offer price.

The company will now push ahead with a retail entitlement offer aiming to raise a further $33 million.

Why is it raising funds?

Healius will use the proceeds from the entitlement offer to reduce its net debt and reset its balance sheet with appropriate gearing.

This capital raising coincides with the company making an agreement with its lenders to waive its gearing covenant for the first half of 2024 and temporarily increase the covenant from 3.5 times to 4 times at 30 June 2024.

Following the completion of the entitlement offer, Healius expects to have sufficient financial flexibility and liquidity. Though, it is worth noting that part of the agreement will see the company suspend its dividend in FY 2024.

Following today's disappointing decline, Healius shares are now down approximately 64% over the last 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Retired couple hugging and laughing.
Broker Notes

Why Macquarie expects this $2.5 billon ASX healthcare share to rocket 36%

Macquarie forecasts strong outperformance for this ASX healthcare share.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Why Mesoblast shares could rise 40% in a year

This biotech could be high risk, high reward picks according to Bell Potter.

Read more »

A elder man and woman lean over their balcony with a cuppa, indicating share rpice movement for ASX retirement shares
Healthcare Shares

Junior health-tech firm's shares race to 12-month high on US regulatory clearance

This healthcare company can start selling in the US after a key regulatory hurdle was overcome.

Read more »

Doctor checking patient's spine x-ray image.
Broker Notes

This All Ords imaging company stock could return more than 50%, one broker says

Deregulation in the MRI sector will be a boon for this billion-dollar outfit, Bell Potter says.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Why did the Mesoblast share price just rocket 13%?

Investors are piling into Mesoblast shares today. But why?

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Junior biotech's shares jump 10% on good news out of the US

This drug developer will soon start recruiting patients for a drug trial after a key tick from the FDA.

Read more »

Falling pills in a blue background symbolising a falling share price.
Healthcare Shares

This ASX 200 biotech's shares are up more than 10% on good news out of the US

This biotech's shares are flying on good regulatory news which makes it easier to buy a key drug.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Cancer drug developer's shares race to three-year high, up 20% on new research results

This cancer drug developer has made a significant step forward in its cancer compound research.

Read more »